MYOK MyoKardia Inc.

53.26
-1.93  -4%
Previous Close 55.19
Open 54.42
Price To Book 5.65
Market Cap 2144818068
Shares 40,270,711
Volume 159,758
Short Ratio
Av. Daily Volume 236,753

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169000
  2. 8-K - Current report 181167068
  3. 8-K - Current report 181071148
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001815
  5. 8-K - Current report 181001491

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2020.
MYK-461 - EXPLORER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 additional interim data due 1Q 2019.
Mavacamten (MYK-461) - PIONEER-OLE
Non-obstructive Hypertrophic cardiomyopathy (HCM)
Phase 2 top-line data due 2H 2019.
Mavacamten (MYK-461) - MAVERICK-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2a top-line data due 4Q 2019.
MYK-491
Heart failure

Latest News

  1. Hedge Funds Are Buying MyoKardia, Inc. (MYOK)
  2. MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
  3. MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
  4. Is MyoKardia Inc (NASDAQ:MYOK) As Strong As Its Balance Sheet Indicates?
  5. Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy — Fundamental Analysis, Key Performance Indications
  6. MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
  7. Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
  8. MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates
  9. MyoKardia: 3Q Earnings Snapshot
  10. All this 500,000-square-foot Berkeley biotech project needs is a developer
  11. MyoKardia Reports Third Quarter 2018 Financial Results
  12. MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
  13. MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
  14. MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
  15. Big pharma leases almost 500,000 square feet for new research center
  16. Bears Are Doing an EKG Test on MyoKardia
  17. MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
  18. Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
  19. MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up?
  20. MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169000
  2. 8-K - Current report 181167068
  3. 8-K - Current report 181071148
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001815
  5. 8-K - Current report 181001491
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 18952553
  7. 8-K - Current report 18902279
  8. 8-K - Current report 18855788
  9. 424B5 - Prospectus [Rule 424(b)(5)] 18855707
  10. 424B5 - Prospectus [Rule 424(b)(5)] 18850710